Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886516 | 0.97 | CAPN1 (0.47) | CAPN1POLBBTKCSNK1DCSNK1E | |
| SCHEMBL22886377 | 0.93 | CAPN1 (0.45) | CAPN1BTK | |
| SCHEMBL22886558 | 0.88 | CAPN1 (0.44) | CAPN1POLBBTK | |
| SCHEMBL22885939 | 0.86 | DCAF1 (0.50) | CAPN1CSNK1DCSNK1ECDK2ALDH1A1 | |
| SCHEMBL22885813 | 0.85 | CAPN1 (0.40) | CAPN1 | |
| SCHEMBL20027721 | 0.85 | CAPN1 (0.55) | CAPN1 | |
| SCHEMBL22886401 | 0.85 | CAPN1 (0.45) | CAPN1CDK2ALDH1A1 | |
| SCHEMBL30133598 | 0.85 | CAPN1 (0.55) | CAPN1 | |
| SCHEMBL22886531 | 0.83 | BTK (0.43) | CAPN1BTK | |
| SCHEMBL22886747 | 0.83 | CAPN1 (0.49) | CAPN1CSNK1DCSNK1EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885POLB 3525/4885BTK 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.